Posted by PeterMartin on October 29, 2016, at 0:54:55
Published today:
http://medicalxpress.com/news/2016-10-medications-depression.html
"For a long time, the blockade of dopamine and norepinephrine reuptake by the antidepressant bupropion within the hypofunctioning central nervous system monoamine systems has remained one of the pharmacological underpinnings for its therapeutic efficacy," Akash Pandhare, M.D., Ph.D., first author of the study and researcher at the TTUHSC Department of Cell Physiology and Molecular Biophysics, said. "This study for the first time established the 5-HT3ARs as a hitherto unidentified molecular target of bupropion."
"The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors," was published in the September issue of the journal Neuropharmacology.
poster:PeterMartin
thread:1092830
URL: http://www.dr-bob.org/babble/20160928/msgs/1092830.html